Literature DB >> 7702890

Do abnormal thyroid stimulating hormone level values result in treatment changes? A study of patients on thyroxine in one general practice.

P De Whalley.   

Abstract

BACKGROUND: Hypothyroidism is a common disorder, easily treated with thyroxine therapy. Thyroid stimulating hormone level assay can detect under- or overtreatment. AIM: A study was carried out in one general practice to discover the number of people on thyroxine therapy, their care, and whether abnormal thyroid stimulating hormone level values resulted in alterations to their thyroxine dose.
METHOD: The study was undertaken in a north Suffolk general practice of 7640 patients. A computer search identified patients receiving repeat prescriptions for thyroxine therapy and their notes were studied. A thyroid stimulating hormone level value in the range of 0.3-3.8 mU l-1 was considered to indicate an appropriate thyroxine dose.
RESULTS: Thyroxine was being taken by 162 patients (2%), of whom 146 were women. Thyroid stimulating hormone level had been checked within the last year for 127 patients (78%). At their last thyroid stimulating hormone level test, 48 patients (30%) had a value above the normal range, only 21 of whom (44%) had their thyroxine dose increased as a result. The thyroid stimulating hormone level was below 0.3 mU l-1 at the last check in 38 patients (23%), only four of whom (11%) had their thyroxine dose reduced as a result.
CONCLUSION: There is often failure to adjust thyroxine dose despite abnormal thyroid stimulating hormone levels. However, more research is needed to determine the ideal thyroid stimulating hormone levels which should be aimed for in these patients, and whether tight control of thyroxine dosage is able to reduce morbidity and mortality among patients with hypothyroidism.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7702890      PMCID: PMC1239143     

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN: 0960-1643            Impact factor:   5.386


  13 in total

1.  Long-term thyroxine treatment and bone mineral density.

Authors:  J A Franklyn; J Betteridge; J Daykin; R Holder; G D Oates; J V Parle; J Lilley; D A Heath; M C Sheppard
Journal:  Lancet       Date:  1992-07-04       Impact factor: 79.321

2.  Long-term L-thyroxine therapy is associated with decreased hip bone density in premenopausal women.

Authors:  T L Paul; J Kerrigan; A M Kelly; L E Braverman; D T Baran
Journal:  JAMA       Date:  1988-06-03       Impact factor: 56.272

Review 3.  Thyroxine replacement treatment and osteoporosis.

Authors:  J A Franklyn; M C Sheppard
Journal:  BMJ       Date:  1990-03-17

4.  Are biochemical tests of thyroid function of any value in monitoring patients receiving thyroxine replacement?

Authors:  W D Fraser; E M Biggart; D S O'Reilly; H W Gray; J H McKillop; J A Thomson
Journal:  Br Med J (Clin Res Ed)       Date:  1986-09-27

5.  The aging thyroid. The use of thyroid hormone in older persons.

Authors:  C T Sawin; A Geller; J M Hershman; W Castelli; P Bacharach
Journal:  JAMA       Date:  1989-05-12       Impact factor: 56.272

6.  Subclinical hyperthyroidism and reduced bone density as a possible result of prolonged suppression of the pituitary-thyroid axis with L-thyroxine.

Authors:  D S Ross; R M Neer; E C Ridgway; G H Daniels
Journal:  Am J Med       Date:  1987-06       Impact factor: 4.965

7.  Thyroxine replacement therapy and circulating lipid concentrations.

Authors:  J A Franklyn; J Daykin; J Betteridge; E A Hughes; R Holder; S R Jones; M C Sheppard
Journal:  Clin Endocrinol (Oxf)       Date:  1993-05       Impact factor: 3.478

8.  Borderline low thyroid function and thyroid autoimmunity. Risk factors for coronary heart disease?

Authors:  M Tièche; G A Lupi; F Gutzwiller; P J Grob; H Studer; H Bürgi
Journal:  Br Heart J       Date:  1981-08

9.  Screening for thyroid disease in a primary care unit with a thyroid stimulating hormone assay with a low detection limit.

Authors:  R Eggertsen; K Petersen; P A Lundberg; E Nyström; G Lindstedt
Journal:  BMJ       Date:  1988-12-17

10.  Clinical versus biochemical assessment in thyroxine replacement therapy: a retrospective study.

Authors:  S H Thomas; I Sturgess; A Wedderburn; J Wylie; D N Croft
Journal:  J R Coll Physicians Lond       Date:  1990-10
View more
  8 in total

1.  Effect of thyroid hormone replacement therapy on cognition in long-term survivors of aneurysmal subarachnoid hemorrhage.

Authors:  Jun Ma; Xinjian Yang; Hao Yin; Yang Wang; Hongbin Chen; Chuangxi Liu; Guoqiang Han; Fangyou Gao
Journal:  Exp Ther Med       Date:  2015-05-07       Impact factor: 2.447

2.  Hormone replacement after thyroid and parathyroid surgery: Target range was missed.

Authors:  Matthias Nauck; Henri Wallaschofski; Anke Hannemann
Journal:  Dtsch Arztebl Int       Date:  2011-02-25       Impact factor: 5.594

3.  Thyroid function tests in patients taking thyroid medication in Germany: Results from the population-based Study of Health in Pomerania (SHIP).

Authors:  Anke Hannemann; Nele Friedrich; Robin Haring; Alexander Krebs; Henry Völzke; Dietrich Alte; Matthias Nauck; Thomas Kohlmann; Hans-Christof Schober; Wolfgang Hoffmann; Henri Wallaschofski
Journal:  BMC Res Notes       Date:  2010-08-16

4.  High frequency of and factors associated with thyroid hormone over-replacement and under-replacement in men and women aged 65 and over.

Authors:  Lily L Somwaru; Alice M Arnold; Neha Joshi; Linda P Fried; Anne R Cappola
Journal:  J Clin Endocrinol Metab       Date:  2009-01-06       Impact factor: 5.958

Review 5.  Cardiovascular and medical ramifications of treatment of subclinical hypothyroidism.

Authors:  Charles J Glueck; Patricia Streicher
Journal:  Curr Atheroscler Rep       Date:  2003-01       Impact factor: 5.113

6.  Metformin and low levels of thyroid-stimulating hormone in patients with type 2 diabetes mellitus.

Authors:  Jean-Pascal Fournier; Hui Yin; Oriana Hoi Yun Yu; Laurent Azoulay
Journal:  CMAJ       Date:  2014-09-22       Impact factor: 8.262

7.  Levothyroxine dose and risk of fractures in older adults: nested case-control study.

Authors:  Marci R Turner; Ximena Camacho; Hadas D Fischer; Peter C Austin; Geoff M Anderson; Paula A Rochon; Lorraine L Lipscombe
Journal:  BMJ       Date:  2011-04-28

8.  Inequitable Long-Term Outcomes for an Indigenous Population After Definitive Treatment of Patients With Graves Disease.

Authors:  Jade A U Tamatea; Kelson Tu'akoi; Goswin Y Meyer-Rochow; John V Conaglen; Marianne S Elston
Journal:  J Endocr Soc       Date:  2019-05-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.